References
- Institute of Medicine Committee to Assess the Science Base for Tobacco Harm Reduction: Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction; edited by K. Stratton, P. Shetty, R. Wallace, and S. Bondurant, National Academy Press, Washington, DC, USA, 2001.
- Royal College of Physicians: Nicotine Without Smoke: Tobacco Harm Reduction; Royal College of Physicians, London, UK, 2016. Available at https://www.rcplondon.ac.uk/projects/outputs/nicotine-without-smoke-tobacco-harm-reduction (accessed March 2022).
- McNeill, A., L.S. Brose, R. Calder, L. Bauld, and D. Robson: Evidence Review of E-Cigarettes and Heated Tobacco Products 2018: A Report Commissioned by Public Health England; Public Health England, London, UK, 2018. Available at https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/684963/Evidence_review_of_e-cigarettes_and_heated_tobacco_products_2018.pdf (accessed February 2022).
- The National Academies of Sciences, Engineering, Medicine: Consensus Study. Public Health Consequences of E-Cigarettes; National Academies Press, Washington, DC, USA, 2018. DOI: 10.17226/24952
- Takahashi, Y., Y. Kanemaru, T. Fukushima, K. Eguchi, S. Yoshida, J. Miller-Holt, and I. Jones: Chemical Analysis and In Vitro Toxicological Evaluation of Aerosol From a Novel Tobacco Vapor Product: A Comparison With Cigarette Smoke; Regul. Toxicol. Pharmacol. 92 (2018) 94–103. DOI: 10.1016/j.yrtph.2017.11.009
- Eaton, D., B. Jakaj, M. Forster, J. Nicol, E. Mavropoulou, K. Scott, C. Liu, K. McAdam, J. Murphy, and C.J. Proctor: Assessment of Tobacco Heating Product THP1.0. Part 2: Product Design, Operation and Thermophysical Characterisation; Regul. Toxicol. Pharmacol. 93 (2018) 4–13. DOI: 10.1016/j.yrtph.2017.09.009
- Schaller, J.-P., D. Keller, L. Poget, P. Pratte, E. Kaelin, D. McHugh, G. Cudazzo, D. Smart, A.R. Tricker, L. Gautier, M. Yerly, R. Reis Pires, S. Le Bouhellec, D. Ghosh, I. Hofer, E. Garcia, P. Vanscheeuwijck, and S. Maeder: Evaluation of the Tobacco Heating System 2.2. Part 2: Chemical Composition, Genotoxicity, Cytotoxicity, and Physical Properties of the Aerosol; Regul. Toxicol. Pharmacol. 81 (2016) S27–S47. DOI: 10.1016/j.yrtph.2016.10.001
- Smith, M.R., B. Clark, F. Lüdicke, J.P. Schaller, P. Vanscheeuwijck, J. Hoeng, and M.C. Peitsch: Evaluation of the Tobacco Heating System 2.2. Part 1: Description of the System and the Scientific Assessment Program; Regul. Toxicol. Pharmacol. 81 (2016) S17–S26. DOI: 10.1016/j.yrtph.2016.07.006
- U.S. Food and Drug Administration (FDA): Modified Risk Orders. IQOS System Holder and Charger; FDA, Silver Spring, MD, USA, 2020. Available at https://www.fda.gov/tobacco-products/advertising-and-promotion/modified-risk-orders (accessed February 2022).
- U.S. Food and Drug Administration (FDA): Guidance for Industry. Modified Risk Tobacco Product Applications. Draft Guidance; FDA, Silver Spring MD, USA, 2012. Available at https://www.fda.gov/media/83300/download (accessed February 2022).
- U.S. Food and Drug Administration (FDA): Section 905(j) Reports: Demonstrating Substantial Equivalence for Tobacco Products. Guidance for Industry and Food and Drug Administration Staff; FDA, Silver Spring, MD, USA, 2011. Available at https://www.fda.gov/-regulatory-information/search-fda-guidance-documents/section-905j-reports-demonstrating-substantial-equivalence-tobacco-products (accessed February 2022)
- Midha, K.K. and G. McKay: Bioequivalence: Its History, Practice, and Future; AAPS J. 11 (2009) 664–670. DOI 10.1208/s12248-009-9142-z
- Schlage, W.K., B. Titz, A. Iskandar, C. Poussin, M. Van der Toorn, E.T. Wong, P. Pratte, S. Maeder, J.P. Schaller, P. Pospisil, S. Boué, G. Vuillaume, P. Leroy, F. Martin, N.V. Ivanov, M.C. Peitsch, and J. Hoeng: Comparing the Preclinical Risk Profile of Inhalable Candidate and Potential Candidate Modified Risk Tobacco Products: A Bridging Use Case; Toxicol. Rep. 7 (2020) 1187–1206. DOI: 10.1016/j.toxrep.2020.09.004
- Proctor, C.: Assessment of Tobacco Heating Product THP1.0. Part 1: Series Introduction; Regul. Toxicol. Pharmacol. 93 (2018) 1–3. DOI: 10.1016/j.yrtph.2017.09.010
- Jaunky, T., J. Adamson, S. Santopietro, A. Terry, D. Thorne, D. Breheny, C. Proctor, and M. Gaça: Assessment of Tobacco Heating Product THP1.0. Part 5: In Vitro Dosimetric and Cytotoxic Assessment; Regul. Toxicol. Pharmacol. 93 (2018) 52–61. DOI: 10.1016/j.yrtph.2017.09.016
- Forster, M., S. Fiebelkorn, C. Yurteri, D. Mariner, C. Liu, C. Wright, K. McAdam, J. Murphy, and C. Proctor: Assessment of Novel Tobacco Heating Product THP1.0. Part 3: Comprehensive Chemical Characterisation of Harmful and Potentially Harmful Aerosol Emissions; Regul. Toxicol. Pharmacol. 93 (2018) 14–33. DOI: 10.1016/j.yrtph.2017.10.006
- Thorne, D., D. Breheny, C. Proctor, and M. Gaça: Assessment of Novel Tobacco Heating Product THP1.0. Part 7: Comparative In Vitro Toxicological Evaluation; Regul. Toxicol. Pharmacol. 93 (2018) 71–83. DOI: 10.1016/j.yrtph.2017.08.017
- Taylor, M., D. Thorne, T. Carr, D. Breheny, P. Walker, C. Proctor, and M. Gaça: Assessment of Novel Tobacco Heating Product THP1.0. Part 6: A Comparative In Vitro Study Using Contemporary Screening Approaches; Regul. Toxicol. Pharmacol. 93 (2018) 62–70. DOI: 10.1016/j.yrtph.2017.08.016
- Murphy, J., C. Liu, K. McAdam, M. Gaça, K. Prasad, O. Camacho, J. McAughey, and C. Proctor: Assessment of Tobacco Heating Product THP1.0. Part 9: The Placement of a Range of Next-Generation Products on an Emissions Continuum Relative to Cigarettes via Pre-Clinical Assessment Studies; Regul. Toxicol. Pharmacol. 93 (2018) 92–104. DOI: 10.1016/j.yrtph.2017.10.001
- Gee, J., K. Prasad, S. Slayford, A. Gray, K. Nother, A. Cunningham, E. Mavropoulou, and C. Proctor: Assessment of Tobacco Heating Product THP1.0. Part 8: Study to Determine Puffing Topography, Mouth Level Exposure and Consumption Among Japanese Users; Regul. Toxicol. Pharmacol. 93 (2018) 84–91. DOI: 10.1016/j.yrtph.2017.08.005
- 21, Forster, M., J. McAughey, K. Prasad, E. Mavropoulou, and C. Proctor: Assessment of Tobacco Heating Product THP1.0. Part 4: Characterisation of Indoor Air Quality and Odour; Regul. Toxicol. Pharmacol. 93 (2018) 34–51. DOI: 10.1016/j.yrtph.2017.09.017
- Health Canada: Official Method T-115 – Determination of “Tar”, Nicotine and Carbon Monoxide in Mainstream Tobacco Smoke; Health Canada, Ottawa, Canada, 1999.
- World Health Organization (WHO): Report on the Scientific Basis of Tobacco Product Regulation – TRS 1015; Study Group on Tobacco Product Regulation, World Health Organization, Geneva, Switzerland, 2019.
- Adamson, J., T. Jaunky, D. Thorne, and M.D. Gaça: Characterisation of the Borgwaldt LM4E System for In Vitro Exposures to Undiluted Aerosols From Next Generation Tobacco and Nicotine Products (NGPs); Food Chem. Toxicol. 113 (2018) 337–344. DOI: 10.1016/j.fct.2018.02.005
- Bishop, E., L. Haswell, J. Adamson, S. Costigan, D. Thorne, and M. Gaça: An Approach to Testing Undiluted E-Cigarette Aerosol In Vitro Using 3D Reconstituted Human Airway Epithelium; Toxicol. In Vitro 54 (2019) 391–401. DOI: 10.1016/j.tiv.2018.01.010
- Azzopardi, D., L.E. Haswell, G. Foss-Smith, K. Hewitt, N. Asquith, S. Corke, and G. Phillips: Evaluation of an Air-Liquid Interface Cell Culture Model for Studies on the Inflammatory and Cytotoxic Responses to Tobacco Smoke Aerosols; Toxicol. In Vitro 29 (2015) 1720–1728. DOI: 10.1016/j.tiv.2015.06.016
- Costigan, S. and C. Meredith: An Approach to Ingredient Screening and Toxicological Risk Assessment of Flavours in E-Liquids; Regul. Toxicol. Pharmacol. 72 (2015) 361–369. DOI: 10.1016/j.yrtph.2015.05.018